Member Info for WeTookPelham

Probably too late and obviously unlikely to get a direct answer, but if anyone attending can carefully/sneakily ask if there are ongoing talks with potential partners/big pharma i.e. basically eek out some juicy info.

Thanks c11, that makes sense.

... there's barely any volume?

Always the way, seems it can drop on small volume but never rise on small volume...hmm.

The SP reaction is a joke, even by Scancells standards. Outstanding results, and yet we see price action not fair off a normal day. It's very very weird.

I do have some solace/hope however, thinking about chester18's valid point:

"It's getting awful close to a point where Bristol Myers Squibb are compelled to make Scancell an Offer or broker a deal for a Worldwide Development and Distribution Partnership"

...does it take for Scancell to have sustained SP rise?

You'd think if any other bio reported the same RNS the SP would have gone to the moon? And can you imagine if a US based bio reported the same news.

IMO it's very odd. Is it just lack of awareness?

"28/11/2023

10:13 chilltime: As below, 12 have seen a 30% reduction (execute details listed for the first 11)

****1 has seen a 100% reduction (they can not find any measurable lesions)***

* Complete Response (CR):

Disappearance of all target lesions

* Partial Response (PR):

At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD

* Progressive Disease (PD):

At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions

* Stable Disease (SD):

Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started

Read Full ThreadReply

28/11/2023

10:09 chilltime: Octopus

Complete response + they are unable to find any trace, no measurable lesions etc.

***In our world it's completely gone, in medical terms they can't find anything to show it exists, no trace"

@TF, that was cleanerworld's post, they couldn't even get a quote for £10 worth of shares, I think?

"Not even £10 TF". Same for 100 shares. Not sure I've seen that before.

Interestingly the approx quote was for 17p.

Yep cannot get a quote either atm.

"Just to add, a positive well written RNS this time. GLA"

In the context of previous Scancell RNS's, this RNS is very bullish, borderline rampy!

Well finally!! About time they stopped the dour, dry and worst of all underselling in their RNS and finally saying it like it actually is! I.e.how good the results actually are, potential partnership interest/market value etc.

I wonder who would have been the writing of this RNS?

IMO this is more than the presentation on Friday.

Quoted 13.774p for 1000 shares ATM.

13p paid also.

Maybe it's like others have said, potential news soon and before the AGM. After all, they do seem to have a lot going on in terms of trials, flying all over the places for networking...you know, actual positive stuff. Doesn't have to be McMillan or 'hype'. Could just be good old fashioned interest in the company.

Also, the crakin inverse indicator.

Never.Ever.Fails.

As mentioned by others I would take the radio silence, especially to emails and calls as somewhat as a good sign, or at the very least, intriguing.

You know when the tomato based puns are dangerously out of control that we are overdue some news :)

Apologies CW, easy to lose track,as Bublé implies, they do seem to be hitting the conference circuit harder than normal?

Https://www.ddw-online.com/what-to-expect-from-pegs-europe-2023-day-1-26944-202311/

"Mireille Vankemmelbeke, PhD, Principal Scientist, Biodiscovery, Scancell, on: ‘Glycan and novel targets for bispecific cancer therapy’."

"...Yet people are asking,' Why don't we get pre-clinical deals like everyone else. Well because SCIB1 and Modi - 1 are actually in clinic so it is impossible to get a pre-clinical deal. Also, I would strongly suggest that we have had a pre-clinical deal of sorts (modi 1) that allows Scancell to maintain it's full rights: Redmile investment.

"Finally, I am sure that the pharma world understands exactly what Scancell are doing and when the time is right, more deals will get done."

Thanks Bojo, good points all very well made. And yes the pre-clinical is (now) kind of a moot point, but my 'argument' as such is, why hasn't they're been a pre-emptive strike of sorts yet i.e. big pharma has seen enough and don't want to risk waiting/competition jumping the gun?

I'm assuming there are NDA's in place, and I'm convinced there will be multiple parties interested in the company/portfolio.

...100k sell.

Patience of a saint rings to mind.

Agree c11, but news of any kind deal/partnering, small or large, won't obviously be provided on any outlook plan.

As violindog says .."WTP....we live in hope : ))"